Friday, May 27, 2022

Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA

 MONTREAL-Friday 27 May 2022 [ AETOS Wire ]


(BUSINESS WIRE) -- On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio).


“Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca.


“After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, channels, and patients across the globe. A need we will now meet through our partnership with SUANFARMA.”


Already an existing partner and supplier of ingredients to Medisca, striking this agreement with SUANFARMA involved reinforcing a well-established symbiotic relationship between two companies committed to world-class quality, service, and price.


“The quality standards set, transparency created, and commitment established between Medisca and Deebio, is what gave us the confidence in choosing Medisca as our primary supplier of Thyroid Powder, USP,” said Gustavo Adolfo Porras, Head of Sales, North America at SUANFARMA. “We look forward to continuing to expand our strong relationship with Medisca.”


For Medisca, the mission is simple – to drive forward worldwide access to qualified products by developing strategic partnerships aligned to the same standards of quality, consistency, and affordability that define Medisca.


Medisca remains the leading supplier of Thyroid Powder, USP to compounding pharmacies. Available for purchase online here.


SUANFARMA will now streamline distribution to Medisca’s supply of Thyroid Powder, USP to other channels and markets.


About MEDISCA®


MEDISCA is a global leader in healthcare with well-established footings in pharmaceutical compounding and advancements in scientific labs, cosmetics, other healthcare industries. For 30+ years, MEDISCA has been serving pharmacies and allied healthcare institutions with cutting-edge offerings and passionate commitment, developing a worldwide network dedicated to personalized medicine. Through genuine relationships, worry-free experiences, convenient processes, and strategic global partnerships, MEDISCA provides top-quality and innovative products, industry-leading services, and world-class support systems. For more information visit www.medisca.com and follow us on Twitter at @medisca.


About SUANFARMA


SUANFARMA founded in 1993, is a B2B life science partner specialized in the development, production, and commercialization of ingredients for the pharmaceutical, veterinary and nutraceutical industries. Our facilities comply with the highest existing regulations in the pharmaceutical industry. With the support of a consolidated and strong commercial network with 12 local offices placed strategically around the world, SUANFARMA provides its services to more than 3.000 active customers in over 70 countries. For more information, visit www.suanfarma.com.


View source version on businesswire.com: https://www.businesswire.com/news/home/20220526005571/en/


Contacts

Panagiota Danopoulos

SVP Global Strategy & Innovation at Medisca

www.medisca.com

1-800-665-6334


OnlyFans Founder Launching Celebrity Trading Card Platform, Zoop, Backed by Polygon

Polygon, the top global blockchain ecosystem, invests in new digital trading card platform created for celebrities, led by former OnlyFans executives


NEW YORK-Friday 27 May 2022 [ AETOS Wire ]


(BUSINESS WIRE) -- Led by a robust team of Web3 developers and former OnlyFans executives, Zoop is set to launch their digital collectable trading platform powered by Polygon, the decentralized Ethereum scaling ecosystem. Zoop’s platform allows users to buy, sell, collect and trade 3D digital playing cards of their favorite celebrities.


On Zoop, fans can acquire officially licensed, limited edition digital cards, and are able to sell and trade them in a secondary market.


“Zoop is the trusted home for authentic celebrity card drops, enabling all fans, regardless of their technical expertise, to participate in the web3.0 space. We hold users' hands as they compete in acquiring digital collectables in the auction process, show off their holdings to friends and ‘collect-to-connect’ with their favorite celebrities of today and tomorrow. Zoop provides access to communities based on the cards users own, and rewards points to users for their interactions with each other and within these communities. We are excited to be launching Summer 2022,” says RJ Phillips, Founder and co-CEO of Zoop. “It’s a win for the celebrities, creates excitement for the fans and a new way for brands to connect with their customers,” he said.


Zoop is capitalizing on the booming blockchain gamification market, which grew to a $40 billion industry in 2021. And, by 2026, the industry is predicted to grow to $147 billion. By opening up the platform and combining it with today’s influencer-driven creator economy, Zoop’s app allows fans to collect 3D digital trading cards from their favorite influencers and celebrities, fostering a closer connection between fan and influencer. Fans can buy, sell, and trade cards, as well as compete in competitions and challenges to gain points, unlocking special rewards including access to like- minded communities. Zoop’s inclusive ecosystem is creating value for digital trading cards by enabling a fully transparent leaderboard.


The Zoop team will be led by co-CEOs Tim Stokely, tech Entrepreneur and founder of OnlyFans, and RJ Phillips. Tim, who will be joining the team in time for the launch this summer, brings extensive knowledge of the creator economy and a proven track record in building a true tech unicorn while RJ’s expertise in growth and scaling make for the perfect leadership team. Together, Tim and RJ plan to leverage their past career successes and knowledge of the creator economy to ultimately scale Zoop into a global digital trading card ecosystem that drives value for both creators and fans alike.


As a precursor to its initial launch, Zoop is offering a limited number of pre-launch Priority Passes (PP), which reward the earlier adopters with a host of perks, both in-app and real-life, in addition to exclusive airdrops only for PP holders. The first batch of these Priority Passes are available now at mint.zoopcards.com.


Zoop will be building its digital marketplace on the globally recognized Polygon blockchain network. Like Zoop, Polygon believes in Web3 for all, making them an ideal partner and blockchain of choice for the Zoop platform. Their low transaction costs and high security standard make card trading on Zoop safe and accessible for all. Additionally, Polygon’s sustainability commitment to make all their NFTs carbon-negative by the end of 2022 was another important factor for Zoop.


“We're delighted to be working with the Zoop team as they build out their platform on Polygon. Zoop aligns with our mission to bring Web3 technologies to a much broader demographic, and allowing fans to connect to their favorite celebrities via Polygon is another step towards this goal," said Michael Blank, COO of Polygon Studios, who has been providing Zoop with a suite of services such as technical support, Web3 game design and distribution, asset expansion and more.


Zoop's announcement comes just weeks after Instagram began minting their non-fungible tokens (NFTs) on Polygon's carbon-neutral network as well.


About Zoop


Zoop is building an entire ecosystem based on officially licensed celebrity digital trading cards. Fans are easily able to buy, sell, trade and collect the celebrities and influencers they idolize and admire through cutting edge blockchain technology. On Zoop, fans can build out their card collections and earn fan rewards with exclusive celebrity experiences whilst forging communities of like-minded collectors. Zoop cards garner authenticity through official partnerships with an unrivaled roster of celebrities and brands onboard. To learn more visit www.zoopcards.com.


Website | Twitter | Telegram | LinkedIn | Discord | Instagram | Facebook | Mint Page | Support Twitter | Medium | Tim’s Instagram | RJ’s Instagram


About Polygon


Polygon is the leading platform for Ethereum scaling and infrastructure development. Its growing suite of products offers developers easy access to all major scaling and infrastructure solutions: L2 solutions (ZK Rollups and Optimistic Rollups), sidechains, hybrid solutions, stand-alone and enterprise chains, data availability solutions, and more. Polygon’s scaling solutions have seen widespread adoption with 19,000+ applications hosted, 3.4B+ total transactions processed, ~135M+ unique user addresses, and $5B+ in assets secured.


If you're an Ethereum Developer, you're already a Polygon developer! Leverage Polygon’s fast and secure txns for your dApp, get started here.


Website | Twitter | Ecosystem Twitter | Developer Twitter | Studios Twitter | Telegram | LinkedIn | Reddit | Discord | Instagram | Facebook


About Polygon Studios


Polygon Studios aims to be the home of the most popular blockchain projects in the world. The Polygon Studios team is focused on supporting developers building decentralized apps on Polygon by providing Web2 and Web3 teams with a suite of services such as developer support, partnership, strategy, go-to-market, and technical integrations. Polygon Studios supports projects from OpenSea to Prada, from Adidas to Draft Kings and Decentral Games to Ubisoft.


Twitter | Facebook | Instagram | Telegram | Tiktok | LinkedIn


DISCLAIMER: Except where otherwise noted, the information contained in this release is as of May 26, 2022. We assume no obligation to update any forward-looking statements contained in this release as a result of new information or future events or developments. We cannot guarantee that any forward-looking statement will be realized. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. Readers are cautioned not to put undue reliance on forward-looking statements.


View source version on businesswire.com: https://www.businesswire.com/news/home/20220526005159/en/


Contacts

Media:

Bryson Greene

zoop@bevelpr.com


Polygon Media:

Katie Olver

polygon@cryptolandpr.com

Trading Central wins at the Technical Analyst Awards

 OTTAWA, Ontario & PARIS-Friday 27 May 2022 [ AETOS Wire ]


(BUSINESS WIRE) -- The Technical Analyst Awards recognize the best in market research, financial data, software and artificial intelligence. At the 2022 edition, industry peers voted Trading Central a winner in three categories: Best AI Product, Most Innovative New Product & Best Multi-Asset Data Provider.


Trading Central’s suite of embeddable apps & APIs power the world’s leading online broker platforms to support investors and active traders throughout their decision making journey. We’re proud to be recognized for our relentless efforts to challenge ourselves, innovate and disrupt the industry.


TC Market Buzz® for Best AI Product 

Read less, know more


TC Market Buzz leverages Artificial Intelligence to make sense of the millions of news headlines, social media posts and articles posted online every day. It replaces static headlines with simple, compelling and informative data visualizations.


Users can:


Identify what instruments are buzzing based on news volume


View the most discussed topics for an instrument


Fact check stories with articles from leading news providers


TC Fundamental Insight® for Most Innovative New Product 

The future of fundamentals


Fundamental investors have to digest mountains of corporate information published by listed companies. Fundamental Insight offers simple interpretations of complex financial data to help users make smart decisions.


TC Quantamental Rating®: A high level view of how a stock is performing.


Target Price: A projection of where a stock could land in 12 months.


Nowcasting: A macroeconomic indicator for insights on asset allocation, sector rotation and price movements.


Trading Central for Best Multi-Asset Data Provider 

One-stop-shop for investment decision support


Trading Central analytics are powerful tools for customer acquisition, engagement and retention. Their suite supports users of all skill-levels who are trading stocks, currencies, cryptos, commodities & more. Trading Central research helps investors find and validate opportunities, time trades, learn about the financial markets, and manage risk.


Alain Pellier, CEO of Trading Central, says, “These awards highlight new products and analytical proficiencies launched by Trading Central over the past year. In our efforts to support brokerage businesses as a one-stop-shop for investment decision support, we’re proud to be recognized by the Technical Analyst Awards as a leader in this ever-changing industry.”


Trading Central recently won in the Financial Research & Data Innovation category at the Fintech Breakthrough Awards.


Learn about Trading Central’s solutions.


View source version on businesswire.com: https://www.businesswire.com/news/home/20220526005502/en/


Contacts

Kasia Flood

marketing@tradingcentral.com


Merck to Present Latest Research From Oncology Portfolio at ASCO 2022

 • 30 abstracts highlighting key data encompassing the Company’s broad oncology clinical portfolio to be presented


DARMSTADT, Germany-Friday 27 May 2022 [ AETOS Wire ]


Not intended for US-, Canada- or UK-based media


(BUSINESS WIRE) -- Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies.


Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN).


“We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of patients with some of the most challenging cancers,” said Victoria Zazulina, Head of Development Unit, Oncology, for the Healthcare business of Merck.


Select presentations include:


BAVENCIO® (avelumab): New analyses of long-term data from the Phase III JAVELIN Bladder 100 study of BAVENCIO as first-line maintenance treatment in advanced UC, including data from subgroups defined by best response to first-line chemotherapy and in patients who did or did not receive second-line treatment after BAVENCIO maintenance.


TEPMETKO® (tepotinib): Data for the oral MET inhibitor TEPMETKO include two poster presentations from the VISION trial reporting efficacy, safety and quality-of-life results of TEPMETKO in Asian patients with METex14 skipping NSCLC, and updated efficacy and safety results of TEPMETKO and exploratory biomarker analyses in patients with NSCLC with high-level MET amplification enrolled into Cohort B of the VISION trial based on liquid biopsy.


ERBITUX® (cetuximab): Abstracts from key investigator-sponsored studies (ISS) exploring ERBITUX-based combinations, including the Phase III FIRE-4 study of early switch-maintenance from ERBITUX/FOLFIRI to bevacizumab/5-FU and rechallenge in later lines for RAS wild-type mCRC patients, and the Phase II AVETUXIRI study evaluating BAVENCIO combined with ERBITUX and irinotecan for refractory microsatellite stable metastatic colorectal cancer.


Berzosertib: Results from research collaborations assessing the intravenous ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor berzosertib, including the National Cancer Institute’s (NCI) Cancer Therapy Evaluation Program 9938 Phase I study of berzosertib plus irinotecan in patients with advanced solid tumors and NCI single-arm Phase II data of berzosertib plus topotecan in patients with relapsed extra-pulmonary small cell neuroendocrine carcinomas.


Below is a selection of key Merck-related abstracts accepted for presentation at ASCO 2022:


Title


Lead Author


Abstract/#


Session Title/Date/Time


BAVENCIO (avelumab)


 


 


 


Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy


BP Valderrama


4559


Genitourinary Cancer—Kidney and Bladder


Saturday, June 4, 2022


1:15 PM-4:15 PM CDT


Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment: exploratory analyses from JAVELIN Bladder 100


J Bellmunt


4560


Genitourinary Cancer—Kidney and Bladder


Saturday, June 4, 2022


1:15 PM-4:15 PM CDT


TEPTMETKO (tepotinib)


 


 


 


Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping


T Kato


9120


Lung Cancer—Non-Small Cell Metastatic


Monday, June 6, 2022


8:00 AM-11:00 AM CDT


Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification (METamp) detected by liquid biopsy (LBx)


X Le


9121


Lung Cancer—Non-Small Cell Metastatic


Monday, June 6, 2022


8:00 AM-11:00 AM CDT


ERBITUX (cetuximab)


 


 


 


Randomized study to investigate a switch maintenance concept with 5-FU plus Bevacizumab after FOLFIRI plus Cetuximab induction treatment versus continued treatment with FOLFIRI plus cetuximab: report of a secondary endpoint of the phase-III FIRE-4 study (AIO KRK-0114)


S Stintzing


3519


 


Gastrointestinal


Cancer—Colorectal and Anal


Saturday, June 4, 2022


8:00 AM - 11:00 AM CDT


Pipeline


 


 


 


Berzosertib (M6620)*


 


 


 


Targeting genomic instability in extrapulmonary small cell neuroendocrine cancers: a phase II study with ATR inhibitor berzosertib and topotecan


N Takahashi


8518


Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers


Monday, June 6, 2022


Live discussion: 12:26 PM CDT


NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors


LC Villaruz


3012


Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology


Sunday, June 5, 2022


Live Discussion: 4:42 PM CDT


*These studies are sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, under its Cooperative Research and Development Agreement with Merck for M6620.


All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.


Commitment to Cancer

Merck is a science-led organization dedicated to delivering transformative medicines with the goal of making a meaningful difference in the lives of people affected by cancer. Our oncology research efforts aim to leverage our synergistic portfolio in oncogenic pathways, immuno-oncology, and DNA Damage Response (DDR) to tackle challenging tumor types in gastrointestinal, genitourinary, and thoracic cancers. Our curiosity drives our pursuit of treatments for even the most complex cancers, as we work to illuminate a path to scientific breakthroughs that transform patient outcomes. Learn more at www.merckgrouponcology.com.


About BAVENCIO® (avelumab)

BAVENCIO is a human anti-programmed death ligand-1 (PD-L1) antibody. BAVENCIO has been shown in preclinical models to engage both the adaptive and innate immune functions. By blocking the interaction of PD-L1 with PD-1 receptors, BAVENCIO has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models.7-9 In November 2014, Merck and Pfizer announced a strategic alliance to co-develop and co-commercialize BAVENCIO.


BAVENCIO Approved Indications

The European Commission (EC) has authorized the use of BAVENCIO as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy. BAVENCIO in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). BAVENCIO is also authorized by the EC for use as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC).


In the US, BAVENCIO is indicated for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy. BAVENCIO is also indicated for the treatment of patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.


BAVENCIO in combination with axitinib is indicated in the US for the first-line treatment of patients with advanced RCC. Additionally, the US Food and Drug Administration (FDA) granted accelerated approval for BAVENCIO for the treatment of adults and pediatric patients 12 years and older with metastatic MCC. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.


BAVENCIO is currently approved for at least one indication for patients in more than 50 countries.


BAVENCIO Safety Profile from the EU Summary of Product Characteristics (SmPC)

The special warnings and precautions for use for BAVENCIO monotherapy include infusion-related reactions, as well as immune-related adverse reactions that include pneumonitis and hepatitis (including fatal cases), colitis, pancreatitis (including fatal cases), myocarditis (including fatal cases), endocrinopathies, nephritis and renal dysfunction, and other immune-related adverse reactions. The special warnings and precautions for use for BAVENCIO in combination with axitinib include hepatotoxicity.


The SmPC list of the most common adverse reactions with BAVENCIO monotherapy in patients with solid tumors includes fatigue, nausea, diarrhea, decreased appetite, constipation, infusion-related reactions, weight decreased and vomiting. The list of most common adverse reactions with BAVENCIO in combination with axitinib includes diarrhea, hypertension, fatigue, nausea, dysphonia, decreased appetite, hypothyroidism, cough, headache, dyspnea, and arthralgia.


About TEPMETKO® (tepotinib)

TEPMETKO is a once-daily oral MET inhibitor that inhibits the oncogenic MET receptor signaling caused by MET (gene) alterations. Discovered and developed in-house at Merck, TEPMETKO has a highly selective mechanism of action, with the potential to improve outcomes in aggressive tumors that have a poor prognosis and harbor these specific alterations.


TEPMETKO was the first oral MET inhibitor to receive a regulatory approval anywhere in the world for the treatment of advanced NSCLC harboring MET gene alterations, with its approval in Japan in March 2020. In February 2021, the U.S. Food and Drug Administration granted accelerated approval to TEPMETKO, making it the first and only once-daily oral MET inhibitor approved for patients in the U.S. with metastatic NSCLC with METex14 skipping alterations. Tepotinib is available in a number of countries, and under review by various other regulatory authorities globally. To meet an urgent clinical need, tepotinib is also available in a pilot zone of China in line with the government policy to drive early access for innovative medicines approved outside of China.


Merck is also investigating the potential role of tepotinib in treating patients with NSCLC and acquired resistance due to MET amplification in the Phase II INSIGHT 2 study of tepotinib in combination with osimertinib in MET amplified, advanced or metastatic NSCLC harboring activating EGFR mutations that has progressed following first-line treatment with osimertinib.


TEPMETKO Safety Profile from the EU Summary of Product Characteristics (SmPC)

The special warnings and precautions for use for TEPMETKO monotherapy include Interstitial lung disease (ILD) or ILD-like adverse reactions including pneumonitis, increase of Liver enzymes (ALT and AST), QTc prolongation, and embryo-foetal toxicity.


The most common adverse reactions in ≥ 20% of exposed to tepotinib at the recommended dose in the target indication are oedema, mainly peripheral oedema, nausea, hypoalbuminaemia, diarrhoea and increase in creatinine. The most common serious adverse reactions in ≥ 1% of patients are peripheral oedema, generalised oedema and ILD.


About Berzosertib (M6620)

Berzosertib is an investigational, intravenous, potent and selective inhibitor of the ataxia telangiectasia and Rad3-related (ATR) protein that blocks ATR activity in cells. Berzosertib is the first ATR inhibitor evaluated in a randomized clinical trial in any tumor type, and it is the lead candidate in Merck’s DNA Damage Response (DDR) inhibitor portfolio. It is currently being investigated in a number of internal and external studies with early phase I/II data in small cell lung cancer, ovarian cancer, and various solid tumors. Berzosertib, formerly known as VX-970, was licensed from Vertex Pharmaceuticals in 2017. Berzosertib is not approved for any use anywhere in the world.


About ERBITUX® (cetuximab)

ERBITUX is an IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). As a monoclonal antibody, the mode of action of ERBITUX is distinct from standard non-selective chemotherapy treatments in that it specifically targets and binds to the EGFR. This binding inhibits the activation of the receptor and the subsequent signal-transduction pathway, which results in reducing both the invasion of normal tissues by tumor cells and the spread of tumors to new sites. It is also believed to inhibit the ability of tumor cells to repair the damage caused by chemotherapy and radiotherapy and to inhibit the formation of new blood vessels inside tumors, which appears to lead to an overall suppression of tumor growth. Based on in vitro evidence, ERBITUX also targets cytotoxic immune effector cells towards EGFR-expressing tumor cells (antibody-dependent cell-mediated cytotoxicity [ADCC]).


ERBITUX has already obtained market authorization in over 100 countries worldwide for the treatment of RAS wild-type metastatic colorectal cancer and for the treatment of squamous cell carcinoma of the head and neck. Merck licensed the right to market ERBITUX, a registered trademark of ImClone LLC, outside the U.S. and Canada from ImClone LLC, a wholly owned subsidiary of Eli Lilly and Company, in 1998.


About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 61,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck generated sales of € 19.7 billion in 66 countries.


Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.


View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005719/en/


Contacts

Noelle Piscitelli

Noelle.Piscitelli@emdserono.com

Phone: +1 781 427-4351



Lenovo Group: Full Year Financial Results 2021/22

  

Lenovo delivers another record year – crossing the US$70 billion revenue milestone and reaching US$2 billion in net income


(BUSINESS WIRE) -- Lenovo Group (HKSE: 992) (ADR: LNVGY) today announced record fiscal year results for the Group, with historic highs for both profit and revenue. Annual net income reached the US$2 billion mark, up 72% year on year, with revenue growing by US$10 billion for the second year running to over US$71 billion. All main business groups were profitable for the full fiscal year - with strong growth momentum in mobile, infrastructure, and solutions and services businesses.


Lenovo successfully overcame macro-environmental challenges and demonstrated both agility and resilience as it navigated industry-wide supply shortages, pandemic disruption, geopolitical uncertainties, and higher inflation to deliver a record year.


The digital and intelligent transformation trend continues to accelerate, presenting the Group with strong growth opportunities. More than 50% of companies now have digitalization as part of their corporate strategy, up from just over one third two years ago. The hybrid work model is a long-term change that will continue to drive strong demand not only for smart devices and data center infrastructure, but also for scenario-driven solutions such as smart collaboration, smart home, and smart office.


Lenovo continued to strengthen its competitiveness to drive sustainable profitable growth. It has already made strong progress toward doubling R&D investments within three years from fiscal year 2021/2022, up 43% year on year to US$2 billion. And will continue to realize its ESG goals and commitments. The company is confident that by leveraging its clear strategy, competing with its unique competitive advantage of global-local model, and the right balance between innovation and efficiency, it can overcome any challenges to capture opportunities.


Lenovo’s Board of Directors declared a final dividend of 3.8 US cents or 30.0 HK cents per share for the fiscal year ended March 31, 2022.


Financial Highlights:


 


FY 21/22


US$ millions


FY 20/21


US$ millions


Change


 


 


Q4 21/22


US$ millions


Q4 20/21


US$ millions


Change


 


Group Revenue


71,618


60,742


18%


16,694


15,630


7%


Pre-tax income


2,768


1,774


56%


520


380


37%


Net Income (profit attributable to equity holders)


2,030


1,178


72%


412


260


58%


 


 


Basic earnings per share (US cents)


17.45


9.54


7.91


3.52


2.19


1.33


Chairman and CEO quote – Yuanqing Yang:


“Although last year was challenging for the world, with the accelerated global digital and intelligent transformation, Lenovo delivered a record year of profit and revenue,” said Yuanqing Yang, Lenovo Chairman and CEO. “All our main businesses are now profitable for the full year, and our new growth engines – SSG, ISG and Mobile – are showing strong momentum. We will capture this window of opportunity, double our R&D investment, drive service-led transformation, realize our ESG goals, and stay flexible and resilient to bring the entire company to new heights.”


Solutions and Services Group (SSG): delivering strong growth and high margins - driving higher overall profitability for the Group


Opportunity:


The trillion-dollar IT services market continues to expand. With the hybrid work model, the demand for digital workplace services is expected to reach US$93 billion by 2025. Equally, research is showing that more than 90% of CIOs are willing to consider adopting as-a-service offerings.


FY21/22 performance:


In the last year SSG delivered high profitability and high growth, with revenue reaching an all-time high of US$5.4 billion, up almost 30% year on year. Operating margin was 22%.


There was strong double-digit growth across all segments, in particular for managed services where revenue grew more than 60% year on year, with strong growth from the TruScale as-a-service business. Project and solution services saw revenue grow 28% year on year, as vertical solutions more than doubled on the previous year.


Revenue from managed services and project and solution services now accounts for almost half of SSG’s business.


Sustainable Growth:


SSG continued to invest in software tools, platforms, and repeatable vertical solutions with Lenovo’s own IP, focusing in particular on driving deeper in vertical solution capabilities in the key industries of manufacturing, retail, healthcare, education, and smart cities.


TruScale as-a-service continued to expand to include broader digital workplace solutions, and the company developed hybrid cloud solutions.


Further exploration of Metaverse solutions continues to be a focus.


Infrastructure Solutions Group (ISG): profitable with record revenue


Opportunity:


ISG continued to benefit from the ICT infrastructure upgrade where the data center market alone is expected to reach US$183 billion by 2025, Edge infrastructure is anticipated to exceed US$41 billion, and the hybrid cloud market will exceed US$120 billion. With data creation expected to double by 2025, the opportunities for data processing and storage will continue to grow.


FY21/22 performance:


ISG hit an important milestone, becoming profitable over the full year, with record revenue of US$7 billion, up more than 13% year-on-year.


All parts of the high-value businesses such as storage, software, services, and HPC set individual revenue records.


Sustainable Growth:


ISG continued to grow premium to the market by enhancing its full stack capabilities that cover both Cloud Service Provider (CSP), and Enterprise/Small and Medium Business (SMB) segments.


Investments in in-house design and manufacturing capabilities will continue, while expanding into fast-growing areas such as edge and cloud services.


ISG further differentiated with green technology such as its Neptune Liquid Cooling system.


Intelligent Devices Group (IDG): record revenue, profitability growth


Opportunity:


The market for smart devices continues to benefit from the new normal of hybrid work. While consumer PC demand may slow in the short term, commercial demand remains strong. IoT endpoint shipments are expected to reach US$2.3 billion in 2025, and the smart collaboration market is expected to surpass US$80 billion by 2025.


FY21/22 performance:


Revenue exceeded US$60 billion for the first time, up 18% year-on-year, and profitability improved by almost US$1 billion year-on-year.


PCs maintained the #1 position as all premium segments delivered year-on-year revenue growth of more than 30%.


Smartphone revenue outgrew the market by 30-points, while doubling operating profit to more than US$360 million, a record since the acquisition of Motorola Mobility.


Expansion beyond PCs continues and now more than 18% of IDG revenue comes from other smart devices, embedded computing/IoT, and scenario-based solutions.


Sustainable Growth:


Lenovo continues its strategy of investing in innovation, particularly in premium segments, to extend its leading position in PCs while maintaining industry-leading profitability.


Further expansion in smartphones, tablets, embedded computing/IoT, and scenario-based solutions such as Smart Collaboration, Smart Home and Smart Office, continues to provide new growth engines.


Q4 Performance


In Q4, despite the disruption to supply and production due to COVID-19 outbreaks in China, Lenovo still closed the final quarter of the year with strong results. Fourth-quarter net Income achieved a year-on-year improvement of more than 50% and revenue grew almost 7% year on year to US$16.7 billion, with all three business groups contributing to the company’s profitable growth. SSG revenue grew 28% and improved its operating margin by more than 1 point year on year. ISG sustained its profitability for the second quarter. IDG improved its operating margin year on year for the 18th consecutive quarter.


Operational highlights and investing for the future


R&D investment - Lenovo recently set out its bold vision for the year ahead that includes hiring 12,000 R&D professionals around the world over the next three years as part of its commitment to double Research and Development investment. Last year, R&D investment grew 43% year on year to reach a historic high exceeding US$2 billion. R&D headcount grew 48% year on year, surpassing 15,000 with one in every five employees now working in R&D. Investments are focused on the New IT architecture, or client-edge-cloud-network-intelligence, and are balanced to optimize between short, medium, and long-term payback.


ESG commitments – After exceeding its 2020 emissions reduction goals a year ahead of schedule, Lenovo has committed to a vision to achieve net-Zero by 2050 and is working with the Science Based Target Initiative to establish goals that support this vision. Lenovo has reported on sustainability topics since 2008, including outlining its work and goals around climate change mitigation, the circular economy, and sustainable materials. In addition to the net-zero vision, Lenovo has committed to positively impacting 15 million lives through philanthropic programs and partnerships by 2025. The company’s philanthropic arm, the Lenovo Foundation, provides smarter technology for all by empowering underrepresented communities with access to technology and STEM education.


About Lenovo


Lenovo (HKSE: 992) (ADR: LNVGY) is a US$70 billion revenue global technology powerhouse, ranked #159 in the Fortune Global 500, employing 75,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver smarter technology for all, Lenovo has built on its success as the world’s leading PC player by expanding into new growth areas of infrastructure, mobile, solutions and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com,and read about the latest news via our StoryHub.


       

 


 

 


 


 


LENOVO GROUP


FINANCIAL SUMMARY


For the fiscal quarter and full year ended March 31, 2022


(in US$ millions, except per share data)


       

 


 

 


 


 


 


 


Q4

FY21/22


Q4

FY20/21


 


Y/Y CHG


 


 


FY21/22


 


FY20/21


 


Y/Y CHG


Revenue


 


16,694


15,630


7%


 


71,618


60,742


18%


Gross profit


 


2,864 


2,688 


7%


 


12,049


9,768


23%


Gross profit margin 


 


17.2% 


17.2% 


0 pts


 


16.8%


16.1%


0.7 pts


Operating expenses


 


(2,275) 


(2,209)


3%


 


(8,968)


(7,588)


18%


R&D expenses


 


(576)


(417)


38%


 


(2,073)


(1,454)


43%


(included in operating expenses)


 

 


 


 


 

 


 


 


 


 

 


 


 


 

 


 


 


Expenses-to-revenue ratio


 


13.6% 


14.1% 


(0.5) pts


 


12.5%


12.5%


0 pts


Operating profit


 


589 


479 


23%


 


3,081


2,180


41%


Other non-operating income/(expenses) – net


 


(69)  


(99) 


(30%)


 


(313)


(406)


(23%)


Pre-tax income


 


520 


380 


37%


 


2,768


1,774


56%


Taxation


 


(99) 


(95) 


4%


 


(623)


(461)


35%


Profit for the period/year


 


421 


285 


48%


 


2,145


1,313


63%


Non-controlling interests


 


(9) 


(25) 


(63%)


 


(115)


(135)


(14%)


Profit attributable to equity holders


 


412


260


58%


 


2,030


1,178


72%


Earnings per share (US cents)


 


 


 


 


 


 


 


 


Basic


 

3.52


2.19


1.33


 

17.45


9.54


7.91


Diluted


 

3.20


1.94


1.26


 

15.77


8.91


6.86


View source version on businesswire.com: https://www.businesswire.com/news/home/20220525006071/en/


Contacts

Press Contacts

Hong Kong – Angela Lee, angelalee@lenovo.com, +852 2516 4810

London – Charlotte West, cwest@lenovo.com, +44 7825 605720

Zeno Group - LenovoWWcorp@zenogroup.com

Thursday, May 26, 2022

SCREEN Increases Efforts to Reduce the Environmental Impact of the Semiconductor Industry

 New Efforts Are Expected to Accelerate Eco-friendly Development Leading to the Realization of a Sustainable Society


KYOTO, Japan-Thursday 26 May 2022 [ AETOS Wire ]


(BUSINESS WIRE) -- SCREEN Semiconductor Solutions Co., Ltd. (SCREEN SPE), a subsidiary of SCREEN Holdings Co., Ltd., has announced it will increase its efforts to reduce the company’s environmental overall impact.


The SCREEN Group is committed to both achieving a sustainable global society and to improving its sustainable value (social value) and has formulated a medium-term management plan titled Sustainable Value 2023 targeting these goals. The plan identifies specific issues in each of the environmental, social, and governance (ESG) fields.


Concerning the environment, SCREEN is working to provide products and services that actively contribute to the reduction of ecological burden. Its efforts include improving the environmental performance of its products, reducing the effects of its business activities on climate change, promoting effective utilization of water resources, increasing recycling of products and parts, and helping to preserve biodiversity.


Concretely, SCREEN SPE seeks to reduce the impact that semiconductor manufacturing processes have on the environment and contribute to the realization of a sustainable global society. As a leading company in the area of cleaning equipment, it is also committed to supporting the growth of the entire semiconductor industry over the long term.


Demand for semiconductor devices has increased on a global scale in recent years, mainly due to the widespread adoption of 5G-compatible smartphones and the growing requirements of data centers accompanying the digital transformation (DX) now occurring worldwide. The growing demand for in-vehicle systems required for electric vehicles and self-driving cars and the rapid spread of IoT infrastructure, especially for industrial equipment, are also driving this change.


However, as reliance on semiconductor devices has grown, the environmental impact created by their manufacturing processes has become a shared concern for the entire semiconductor industry. Issues that must be addressed include high energy consumption and the use of chemical substances, scarce materials, and ultrapure water, and the emission of greenhouse gases.


With this trend in mind, SCREEN SPE has agreed to join the Sustainable Semiconductor Technologies and Systems (SSTS)* research program led by imec, a world-leading research and innovation hub based in Leuven, Belgium. The SSTS program is designed to help the semiconductor industry reduce its overall environmental impact.

Led by Director Lars-Ake Ragnarsson, the new program leverages imec’s expertise in the areas of infrastructure, technology, and equipment. This includes using concrete, highly reliable models plus detailed carbon footprint analyses to predict the effects of manufacturing processes on the environment. The initiative is ultimately intended to support the entire semiconductor value chain in decreasing its ecological footprint.


By joining the SSTS program, SCREEN SPE hopes to accelerate its development of environmentally friendly manufacturing equipment, particularly semiconductor cleaning and coater/developer systems. It expects the decision to enable it to provide the industry with products offering even greater environmental performance.


imec Press release

Imec unites partners from the semiconductor value chain to jointly target net-zero emissions for chip manufacturing


*SSTS (Sustainable Semiconductor Technologies and Systems)


View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005556/en/


Contacts

SCREEN Holdings Co., Ltd.

Public Relations Division, PR & IR Department

Maki Yamamoto, Atsushi Kurosaki,

+81-75-414-7131

nr-info@screen.co.jp


NEC and Juniper Networks Deploy Algeria Telecom’s Nationwide 5G-Ready IP Metro Network


 Network automation tools deployed to drive assured user experience

TOKYO & SUNNYVALE, Calif-Thursday 26 May 2022 [ AETOS Wire ]


(BUSINESS WIRE) -- NEC Corporation (NEC; TSE: 6701), a leading global IT and network transformation services provider, and Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced they have worked with Algeria Telecom, the leader in the Algerian telecommunications market, to roll out its modernized, nationwide IP metro commercial network to support current demand for increased capacity as well as future needs driven by 5G and FTTx.


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005904/en/


Algeria Telecom has formed a mid-term strategic plan to implement a transport network with a homogenized, optimized topology as well as automation capabilities that guarantee bandwidth and future-proofing of its infrastructure in a growing market. NEC and Juniper have successfully delivered Algeria Telecom’s next generation IP metro network while ensuring quality of service, driving toward the best possible user experience, at scale.


As the innovative foundation of the new platform, Algeria Telecom has selected high-performing, secure solutions from the Juniper Networks portfolio for SDN-ready, cloud-grade networking and feature-rich, simple and secure connectivity at scale, deployed as access nodes to create separate pre-aggregation, aggregation and access domains for optimal reliability. Elements of the Juniper Paragon Automation cloud-native solution suite, Paragon Pathfinder and Paragon Planner have been deployed, enabling Algeria Telecom to achieve deep visibility and simplified operations of its network and services. This paves the way for assured user experiences within complex 5G and multicloud services. All of the Juniper platforms run on a single operating system, Junos® OS, to create an easily-managed, simplified and open solution.


NEC leveraged its extensive transport network integration and engineering capabilities to skillfully deliver best-in-class solutions that are dynamically tailored for Algeria Telecom’s requirements. Moreover, NEC orchestrated the total project as a ‘One-Stop Network Integrator’, capitalizing on its professional services based on global and local experiences ranging from network analysis and consulting, to design, implementation, migration and operation of high-capacity networks.


In addition, NEC and Juniper’s solid partnership, built on a track record of delivering innovative networking to hundreds of customers across the globe, has enabled the tight coordination between the parties to achieve Algeria Telecom’s objective of providing a high-capacity innovative network to accommodate surging data traffic and a future of diversified 5G use cases.


"The successful completion of the IP metro network modernization project by our partners, NEC Corporation and Juniper Networks, will allow us to make the migration to IPV6 and the initiation of digital transformation, as well as the implementation of high speed internet, as we best satisfy the needs of Algeria Telecom customers," said Mr. Adel Bentoumi, CEO of Algeria Telecom.


“The rapid growth of network traffic is a clear indication of the need for modernization and expansion of network capacity,” said Allahoum Hocine, Head of IP Core, Algeria Telecom. “NEC and Juniper have been extremely attentive to our needs, both technical and commercial, working as an extension of our team with their outstanding local engineering abilities, as well as their relentless efforts to assure quality of experience and on-time delivery. Overall, the innovative solutions from Juniper to enable this automated metro cloud architecture have helped us achieve our strategic goals and thrive as we pave the way for 5G.”


“Networks have always been a key asset for service providers, but going forward they will be the foundation for every aspect of business transformation in the 5G and cloud era. Algeria Telecom is jumping ahead of the curve by investing in an open, agile and automated network architecture that can drive simplified operations, improved economics and superior end-user experiences,” said Brendan Gibbs, Senior Vice President, Automated WAN Solutions, Juniper Networks.


“Our customer-first approach and uncompromising quality are values that are deeply ingrained in our culture,” said Hideyuki Ogata, General Manager, Service Provider Solutions Department, NEC Corporation. “This, combined with our accumulated domain expertise at NEC 5G Transport Network Center of Excellence (CoE) in EMEA, makes us confident that our extended engagement through this partnership will help enable continuous success and advancement of Algeria Telecom’s business.”


Additional Resources:

The NEC-Juniper Global Alliance


About Algeria Telecom


Algeria Telecommunications Corporation (French: Algérie Télécom) is the state owned telecom operator in Algeria. It is a public company active in the fields of fixed phone and internet. Algérie Télécom was created on 5 August 2000.


For more information, visit Algeria Telecom at www.algerietelecom.dz


About Juniper Networks


Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.


Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.


About NEC Corporation


NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at http://www.nec.com.


LinkedIn: https://www.linkedin.com/company/nec/

YouTube: https://www.youtube.com/user/NECglobalOfficial

Facebook: https://www.facebook.com/nec.global/

Twitter: https://twitter.com/NEC_corp


NEC is a registered trademark of NEC Corporation. All Rights Reserved. Other product or service marks mentioned herein are the trademarks of their respective owners. ©2022 NEC Corporation.


View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005904/en/


Contacts

Penny Still

Juniper Networks

pstill@juniper.net

+44 (0) 1372 385 692


Joseph Jasper

NEC Corporation

j-jasper@nec.com